$147 Million is the total value of Birchview Capital, LP's 0 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 20.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | Sell | CELGENE CORP (CELG) | $54,496,000 | -13.9% | 686,181 | -3.2% | 37.04% | -11.1% |
| AXDX | ACCELERATE DIAGNOSTICS INC | $48,699,000 | -2.4% | 2,183,795 | 0.0% | 33.10% | +0.7% | |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $4,912,000 | +13.0% | 50,000 | -4.6% | 3.34% | +16.6% |
| CFRX | Sell | CONTRAFECT CORP | $2,376,000 | +28.8% | 1,075,082 | -5.3% | 1.62% | +32.9% |
| QDEL | QUIDEL CORP | $2,259,000 | +28.4% | 33,975 | 0.0% | 1.54% | +32.4% | |
| ARRY | Buy | ARRAY BIOPHARMA INC | $2,148,000 | +17.5% | 128,000 | +14.3% | 1.46% | +21.3% |
| ECA | Buy | ENCANA CORP | $2,118,000 | +45.6% | 162,300 | +22.7% | 1.44% | +50.2% |
| EQT | Sell | EQT CORP | $2,113,000 | +5.1% | 38,300 | -9.5% | 1.44% | +8.5% |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $2,028,000 | -8.1% | 157,303 | -11.3% | 1.38% | -5.2% |
| VRML | Sell | VERMILLION INC | $1,742,000 | -45.8% | 2,232,933 | -5.5% | 1.18% | -44.0% |
| VNDA | VANDA PHARMACEUTICALS INC | $1,676,000 | +13.0% | 88,000 | 0.0% | 1.14% | +16.6% | |
| SLNO | SOLENO THERAPEUTICS INC | $1,588,000 | +29.1% | 678,428 | 0.0% | 1.08% | +33.2% | |
| ALBO | Buy | ALBIREO PHARMA INC | $1,349,000 | +72.5% | 38,000 | +58.3% | 0.92% | +78.1% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $1,250,000 | +39.4% | 34,000 | +47.8% | 0.85% | +43.8% |
| SIEN | SIENTRA INC | $1,235,000 | +102.1% | 63,300 | 0.0% | 0.84% | +108.7% | |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $1,090,000 | +175.9% | 25,000 | +150.0% | 0.74% | +185.0% |
| GTHX | G1 THERAPEUTICS INC | $956,000 | +17.3% | 22,000 | 0.0% | 0.65% | +21.0% | |
| VCYT | Sell | VERACYTE INC | $922,000 | +39.7% | 98,767 | -16.8% | 0.63% | +44.1% |
| CMTA | Buy | CLEMENTIA PHARMACEUTICALS INC | $895,000 | +55.4% | 68,000 | +78.9% | 0.61% | +60.4% |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $850,000 | – | 50,000 | +100.0% | 0.58% | – |
| CORT | Sell | CORCEPT THERAPEUTICS INC | $786,000 | -36.7% | 50,000 | -33.8% | 0.53% | -34.7% |
| MASI | MASIMO CORP | $781,000 | +10.9% | 8,000 | 0.0% | 0.53% | +14.4% | |
| T107PS | WRIGHT MEDICAL GROUP NV | $779,000 | +30.9% | 30,000 | 0.0% | 0.53% | +34.9% | |
| VYGR | VOYAGER THERAPEUTICS INC | $645,000 | +4.0% | 33,000 | 0.0% | 0.44% | +7.4% | |
| AXGN | Sell | AXOGEN INC | $603,000 | -8.2% | 12,000 | -33.3% | 0.41% | -5.3% |
| XLRN | Sell | ACCELERON PHARMA INC | $582,000 | -40.5% | 12,000 | -52.0% | 0.40% | -38.5% |
| BIIB | BIOGEN INC | $580,000 | +5.8% | 2,000 | 0.0% | 0.39% | +9.1% | |
| PXD | PIONEER NATURAL RESOURCES CO | $568,000 | +10.3% | 3,000 | 0.0% | 0.39% | +13.9% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $551,000 | +28.1% | 45,000 | 0.0% | 0.37% | +32.2% | |
| FOLD | AMICUS THERAPEUTICS INC | $531,000 | +3.9% | 34,000 | 0.0% | 0.36% | +7.1% | |
| IFRX | New | INFLARX NV | $516,000 | – | 16,000 | +100.0% | 0.35% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $464,000 | – | 9,500 | +100.0% | 0.32% | – |
| XNCR | XENCOR INC | $455,000 | +23.3% | 12,300 | 0.0% | 0.31% | +27.2% | |
| IMMY | New | IMPRIMIS PHARMACEUTICALS INC | $396,000 | – | 180,000 | +100.0% | 0.27% | – |
| YTEN | YIELD10 BIOSCIENCE INC | $382,000 | -27.7% | 270,759 | 0.0% | 0.26% | -25.3% | |
| MYGN | MYRIAD GENETICS INC | $374,000 | +26.4% | 10,000 | 0.0% | 0.25% | +30.3% | |
| TSRO | TESARO INC | $365,000 | -22.2% | 8,200 | 0.0% | 0.25% | -19.7% | |
| SITOQ | SITO MOBILE LTD | $363,000 | -35.5% | 140,000 | 0.0% | 0.25% | -33.4% | |
| ICPT | INTERCEPT PHARMACEUTICALS INC | $361,000 | +36.2% | 4,300 | 0.0% | 0.24% | +40.0% | |
| APTX | New | APTINYX INC | $242,000 | – | 10,000 | +100.0% | 0.16% | – |
| OMED | ONCOMED PHARMACEUTICALS INC | $228,000 | -27.4% | 98,689 | 0.0% | 0.16% | -25.1% | |
| CLVS | CLOVIS ONCOLOGY INC | $227,000 | -14.0% | 5,000 | 0.0% | 0.15% | -11.5% | |
| AVEO | AVEO PHARMACEUTICALS INC | $226,000 | -22.1% | 100,000 | 0.0% | 0.15% | -19.4% | |
| SLDB | Sell | SOLID BIOSCIENCES INC | $214,000 | +42.7% | 6,000 | -70.0% | 0.14% | +46.5% |
| TGTX | New | TG THERAPEUTICS INC | $197,000 | – | 15,000 | +100.0% | 0.13% | – |
| IRONWOOD PHARMACEUTICALS INC | $191,000 | +24.0% | 10,000 | 0.0% | 0.13% | +28.7% | ||
| BIOL | Sell | BIOLASE INC | $165,000 | -68.4% | 136,180 | -89.4% | 0.11% | -67.4% |
| GNCA | GENOCEA BIOSCIENCES INC | $162,000 | -18.2% | 189,000 | 0.0% | 0.11% | -15.4% | |
| GNMX | AEVI GENOMIC MEDICINE INC | $142,000 | -44.7% | 128,000 | 0.0% | 0.10% | -42.6% | |
| ECYT | New | ENDOCYTE INC | $138,000 | – | 10,000 | +100.0% | 0.09% | – |
| CELGZ | CELGENE CORP (CELGZ)right 12/31/2030 | $98,000 | +40.0% | 241,877 | 0.0% | 0.07% | +45.7% | |
| CYTK | CYTOKINETICS INC | $83,000 | +15.3% | 10,000 | 0.0% | 0.06% | +19.1% | |
| WKHS | Sell | WORKHORSE GROUP INC | $46,000 | -65.2% | 25,000 | -50.0% | 0.03% | -64.4% |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -39,700 | -100.0% | -0.12% | – |
| ABLX | Exit | ABLYNX NV | $0 | – | -5,000 | -100.0% | -0.18% | – |
| SHPG | Exit | SHIRE PLC | $0 | – | -2,700 | -100.0% | -0.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-02
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.